Cargando…
Schisandrin B ameliorates non‐alcoholic liver disease through anti‐inflammation activation in diabetic mice
Type 2 diabetes mellitus (T2DM) is a metabolic risk factor associated with non‐alcoholic liver disease (NAFLD). Schisandrin B (Sch B) is a promising agent for NAFLD. However, the actions of Sch B on diabetes‐associated NAFLD and the underlying mechanisms are not characterized. This study aimed to as...
Autores principales: | Ma, Ruojia, Zhan, Yike, Zhang, Yamei, Wu, Liangan, Wang, Xing, Guo, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299884/ https://www.ncbi.nlm.nih.gov/pubmed/34927282 http://dx.doi.org/10.1002/ddr.21905 |
Ejemplares similares
-
Therapeutic effect of Schisandrin A on avian colibacillosis through gut-liver axis
por: Bao, Jialu, et al.
Publicado: (2021) -
Differential Action between Schisandrin A and Schisandrin B in Eliciting an Anti-Inflammatory Action: The Depletion of Reduced Glutathione and the Induction of an Antioxidant Response
por: Leong, Pou Kuan, et al.
Publicado: (2016) -
Schisandrin B ameliorated chondrocytes inflammation and osteoarthritis via suppression of NF-κB and MAPK signal pathways
por: Ran, Jisheng, et al.
Publicado: (2018) -
Ameliorative effects of Schisandrin B on Schistosoma mansoni-induced hepatic fibrosis in vivo
por: Lam, Ho Yin Pekkle, et al.
Publicado: (2021) -
Flaxseed oil ameliorates alcoholic liver disease via anti-inflammation and modulating gut microbiota in mice
por: Zhang, Xiaoxia, et al.
Publicado: (2017)